GB-4362 Clinical Trials (2026): 1 Studies for Advanced Urothelial Cancer & Metastatic Urothelial Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GB-4362 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Urothelial Cancer & Metastatic Urothelial Carcinoma) and 37 total planned enrollment. 1 GB-4362 clinical trial is actively recruiting at 7 U.S. sites across 6 states. Most recent activity: NCT07484022 (Dec 2027).
Where to Participate: All GB-4362 Trial Sites in the U.S. (7 sites across 6 states)
Every actively recruiting GB-4362trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope | Duarte91010 | NCT07484022 | Map |
| FL | Orlando Health | Orlando32806 | NCT07484022 | Map |
| GA | Southeastern Regional Medical Center | Tucker30084 | NCT07484022 | Map |
| IL | Midwestern Regional Medical Center | Zion60099 | NCT07484022 | Map |
| NY | Start New York, LLC | Lake Success11042 | NCT07484022 | Map |
| NY | MSK | New York10065 | NCT07484022 | Map |
| VA | The University of Virgina | Charlottesville22908 | NCT07484022 | Map |
GB-4362 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting GB-4362 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | P1 | Advanced Urothelial Cancer | 37 | Jun 2026 |
All GB-4362 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | P1 | recruiting | 37 | Generate Biomedicines | Jun 2026 |
GB-4362 clinical trials: frequently asked questions
- How many GB-4362 clinical trials are there?
- 1 GB-4362 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GB-4362 clinical trials recruiting in 2026?
- Yes — 1 GB-4362 trial is actively recruiting in 2026, with 7 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GB-4362 being studied for?
- GB-4362 is being studied for Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma. The trials are grouped by indication on this page.
- What phase is GB-4362 in?
- GB-4362 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GB-4362 clinical trials?
- The lead sponsor across the most GB-4362 trials is Generate Biomedicines. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GB-4362as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: